An interventional study of Olympus and Cellvizio in Esophageal Neoplasms, sponsored by King Chulalongkorn Memorial Hospital. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-08-28.
Sponsored by King Chulalongkorn Memorial Hospital · Not applicable, Interventional, and Diagnostic
This descriptive cross sectional study aims to directly compare the diagnostic capability of the probed-based confocal laser endomicroscopy (pCLE) and the magnifying narrow band imaging (M-NBI) in the Lugol's voiding lesions.
9,359 studies on the registry are indexed under Neoplasms; 2,486 are open to participants now.
This study's enrollment of 44 is below the median of 50 across 7,250 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →King Chulalongkorn Memorial Hospital is the lead sponsor of 42 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
probe-based confocal laser endomicroscopy narrow band imaging with magnification
Device: Olympus · Device: Cellvizio
narrow band imaging with magnification
probe-based confocal laser endomicroscopy
Accuracy
Diagnostic performance of the pCLE and M-NBI in Lugol's voiding lesions size larger than 5 millimeters.
Time frame: an expected average of 2 weeks
There were 631 patients with a previous history of head and neck cancer in the 10-year record. Of the 631 patients, 587 were excluded for the following reasons: patients could not be contacted (n=458), death (n=72), esophageal obstruction or stricture, previous esophageal surgery (n=34), and patients who refused to participate (n=23).
| Milestone | Study Arm |
|---|---|
| Started | 44 |
| Completed | 44 |
| Not completed | 0 |
Diagnostic performance of the pCLE and M-NBI in Lugol's voiding lesions size larger than 5 millimeters.
| Percentage of accuracy | Study Arm |
|---|---|
| pCLE | 89 (67 to 97) |
| dNBI | 70 (48 to 85) |
Collected over Intraprocedural.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Study Arm | 0/44 (0%) | 0/44 (0%) | 1/44 (2.3%) |
| Event | Study Arm |
|---|---|
| BleedingSurgical and medical procedures | 1/44 |
| Age, Continuous(years) | Study Arm |
|---|---|
| Mean | 60 ± 12 |
| Sex: Female, Male(Participants) | Study Arm |
|---|---|
| Female | 6 |
| Male | 38 |
| Race and Ethnicity Not Collected(Participants) | Study Arm |
|---|
| Region of Enrollment(Participants) | Study Arm |
|---|---|
| Thailand | 44 |
No study locations are listed for this record.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King Chulalongkorn Memorial Hospital